BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23551429)

  • 21. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms--a case-control study in an Omani population.
    Al-Moundhri MS; Al-Nabhani M; Burney IA; Al-Farsi AA; Al-Bahrani B
    Mol Carcinog; 2009 Dec; 48(12):1170-6. PubMed ID: 19676106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The VEGFR-2 protein and the VEGFR-2 rs1870377 A>T genetic polymorphism are prognostic factors for gastric cancer.
    Zhu X; Wang Y; Xue W; Wang R; Wang L; Zhu ML; Zheng L
    Cancer Biol Ther; 2019; 20(4):497-504. PubMed ID: 30380970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
    Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
    Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma.
    Kim JY; Bae BN; Kwon JE; Kim HJ; Park K
    APMIS; 2011 Jul; 119(7):449-59. PubMed ID: 21635552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SLITRK3 expression correlation to gastrointestinal stromal tumor risk rating and prognosis.
    Wang CJ; Zhang ZZ; Xu J; Wang M; Zhao WY; Tu L; Zhuang C; Liu Q; Shen YY; Cao H; Zhang ZG
    World J Gastroenterol; 2015 Jul; 21(27):8398-407. PubMed ID: 26217092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.
    Eng L; Azad AK; Qiu X; Kong QQ; Cheng D; Ying N; Tse A; Kuang Q; Dodbiba L; Renouf DJ; Marsh S; Savas S; Mackay HJ; Knox JJ; Darling GE; Wong RK; Xu W; Liu G; Faluyi OO
    Carcinogenesis; 2015 Sep; 36(9):956-62. PubMed ID: 26014353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer.
    Martins SF; Garcia EA; Luz MA; Pardal F; Rodrigues M; Filho AL
    Cancer Genomics Proteomics; 2013; 10(2):55-67. PubMed ID: 23603341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
    Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Uchida Y
    Cancer; 2003 Jan; 97(2):457-64. PubMed ID: 12518370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.
    Kojima H; Shijubo N; Yamada G; Ichimiya S; Abe S; Satoh M; Sato N
    Cancer; 2005 Oct; 104(8):1668-77. PubMed ID: 16116610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma.
    Capp C; Wajner SM; Siqueira DR; Brasil BA; Meurer L; Maia AL
    Thyroid; 2010 Aug; 20(8):863-71. PubMed ID: 20615131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.
    Pallaud C; Reck M; Juhasz E; Szima B; Yu CJ; Burdaeva O; Orlov S; Hilton M; Archer V; Mok T
    Lung Cancer; 2014 Oct; 86(1):67-72. PubMed ID: 25154982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular endothelial growth factor ‑634G/C polymorphism is associated with increased breast cancer risk and aggressiveness.
    Sa-Nguanraksa D; Chuangsuwanich T; Pongpruttipan T; Kummalue T; Rojananin S; Ratanawichhitrasin A; Prasarttong-Osoth P; Chuthatisith S; Pisarnturakit P; Aeumrithaicharoenchok W; Rushatamukayanunt P; Lohsiriwat V; Boonsripitayanon M; Malasit P; O-Charoenrat P
    Mol Med Rep; 2013 Oct; 8(4):1242-50. PubMed ID: 23904001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).
    Martín J; Poveda A; Llombart-Bosch A; Ramos R; López-Guerrero JA; García del Muro J; Maurel J; Calabuig S; Gutierrez A; González de Sande JL; Martínez J; De Juan A; Laínez N; Losa F; Alija V; Escudero P; Casado A; García P; Blanco R; Buesa JM;
    J Clin Oncol; 2005 Sep; 23(25):6190-8. PubMed ID: 16135486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.
    Mylona E; Alexandrou P; Mpakali A; Giannopoulou I; Liapis G; Markaki S; Keramopoulos A; Nakopoulou L
    Eur J Surg Oncol; 2007 Apr; 33(3):294-300. PubMed ID: 17129704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C>T) gene and patients with stomach cancer.
    Bae SJ; Ahn DH; Hong SP; Kang H; Hwang SG; Oh D; Kim NK
    Yonsei Med J; 2008 Oct; 49(5):783-91. PubMed ID: 18972599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer.
    Koutras A; Kotoula V; Fountzilas G
    Pharmacogenomics; 2015 Jan; 16(1):79-94. PubMed ID: 25560472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.
    Uzunoglu FG; Kaufmann C; Wikman H; Güngör C; Bohn BA; Nentwich MF; Reeh M; Pantel K; Bockhorn M; Kutup A; Mann O; Izbicki JR; Vashist YK
    Ann Surg Oncol; 2012 Jul; 19(7):2159-68. PubMed ID: 22395975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VEGF polymorphisms may be associated with susceptibility to colorectal cancer: a case-control study.
    Antonacopoulou AG; Kottorou AE; Dimitrakopoulos FI; Triantafyllia V; Marousi S; Koutras A; Kalofonos HP
    Cancer Biomark; 2011; 10(5):213-7. PubMed ID: 22699782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma.
    Rivet J; Mourah S; Murata H; Mounier N; Pisonero H; Mongiat-Artus P; Teillac P; Calvo F; Janin A; Dosquet C
    Cancer; 2008 Jan; 112(2):433-42. PubMed ID: 18041056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma.
    Brito AB; Lourenço GJ; Oliveira GB; De Souza CA; Vassallo J; Lima CS
    Ann Hematol; 2014 Aug; 93(8):1363-9. PubMed ID: 24687381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.